We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.2B
AUM Growth
-$978M
Cap. Flow
-$700M
Cap. Flow %
-13.47%
Top 10 Hldgs %
44.11%
Holding
176
New
13
Increased
49
Reduced
69
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.9M
2
BRKR icon
Bruker
BRKR
+$21.3M
3
AMGN icon
Amgen
AMGN
+$19M
4
EHC icon
Encompass Health
EHC
+$16.6M
5
THC icon
Tenet Healthcare
THC
+$15.6M

Top Sells

Rank Stock Value
1
OPCH icon
Option Care Health
OPCH
+$51.8M
2
EPIX
ESSA Pharma
EPIX
+$47.8M
3
EXAS
Exact Sciences
EXAS
+$47M
4
CDNA icon
CareDx
CDNA
+$43.1M
5
EXEL icon
Exelixis
EXEL
+$41.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Industrials 0.04%
3 Communication Services 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMDX icon
76
Transmedics
TMDX
$2.52B
$12M 0.23%
192,718
+22,874
+13% +$2.13M
BIO icon
77
Bio-Rad Laboratories Class A
BIO
$8.14B
$11M 0.21%
33,551
-12,600
-27% -$4.28M
MCK icon
78
McKesson
MCK
$97.6B
$11M 0.21%
19,315
-16,427
-46% -$9.2M
PHR icon
79
Phreesia
PHR
$658M
$10.2M 0.2%
405,693
-16,713
-4% -$357K
AXSM icon
80
Axsome Therapeutics
AXSM
$11.7B
$10.1M 0.19%
118,930
-248,251
-68% -$22.8M
CRL icon
81
Charles River Laboratories
CRL
$10.5B
$9.29M 0.18%
50,327
-22,788
-31% -$4.39M
GKOS icon
82
Glaukos
GKOS
$9.22B
$9.13M 0.18%
60,875
-2,108
-3% -$290K
IQV icon
83
IQVIA
IQV
$34.1B
$8.81M 0.17%
44,833
-84,994
-65% -$17.9M
ABBV icon
84
AbbVie
ABBV
$449B
$8.04M 0.15%
45,259
+2,373
+6% +$436K
FATE icon
85
Fate Therapeutics
FATE
$328M
$7.99M 0.15%
4,839,779
– –
JNJ icon
86
Johnson & Johnson
JNJ
$605B
$7.89M 0.15%
54,557
+3,315
+6% +$514K
HUM icon
87
Humana
HUM
$47.9B
$7.2M 0.14%
28,367
-73
-0.3% -$19.6K
ALT icon
88
Altimmune
ALT
$546M
$6.82M 0.13%
945,446
+81,786
+9% +$625K
ASTH icon
89
Astrana Health
ASTH
$2.22B
$6.47M 0.12%
205,239
-48,943
-19% -$2.32M
ONC
90
BeOne Medicines Ltd
ONC
$32.3B
$6.32M 0.12%
34,229
-24,500
-42% -$5.01M
TERN
91
DELISTED
Terns Pharmaceuticals
TERN
$5.88M 0.11%
1,061,753
+19,618
+2% +$133K
ILMN icon
92
Illumina
ILMN
$28B
$5.84M 0.11%
43,703
-1,493
-3% -$213K
WAY
93
Waystar Holding Corp
WAY
$4.28B
$5.79M 0.11%
157,898
+7,696
+5% +$237K
LEGN icon
94
Legend Biotech
LEGN
$4.54B
$5.45M 0.1%
167,341
-1,793
-1% -$74.3K
CNC icon
95
Centene
CNC
$32.9B
$5.24M 0.1%
86,456
-252
-0.3% -$15.7K
GILD icon
96
Gilead Sciences
GILD
$166B
$4.47M 0.09%
48,429
+2,402
+5% +$216K
OMCL icon
97
Omnicell
OMCL
$2.08B
$4.22M 0.08%
94,740
-102,974
-52% -$4.63M
MASI
98
DELISTED
Masimo
MASI
$3.99M 0.08%
+24,166
New +$3.82M
TXG icon
99
10x Genomics
TXG
$5.42B
$3.89M 0.07%
270,728
-11,153
-4% -$176K
PFE icon
100
Pfizer
PFE
$142B
$3.76M 0.07%
141,560
+485
+0.3% +$13.2K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2024 Portfolio in Review

As of Q4 2024, Bellevue Group held 176 positions worth $5.2B, down 16% from $6.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Bellevue Group withdrew a net $700M in Q4 2024, closing 15 positions and reducing 69 holdings. Its most notable exit was Option Care Health, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Bruker worth $21.1M.

  • Bellevue Group's largest Q4 2024 buy was Bruker: 359,588 shares worth $21.1M.
  • Bellevue Group added most to Merck in Q4 2024, an estimated $22.9M increase.
  • Bellevue Group's biggest Q4 2024 reduction was Exact Sciences, cutting an estimated $47M.
  • Bellevue Group fully exited Option Care Health in Q4 2024, selling an estimated $51.8M.
  • Bellevue Group's ten largest holdings make up 44% of its $5.2B portfolio in Q4 2024.
  • Bellevue Group opened 13 new positions and closed 15 in Q4 2024.
  • Bellevue Group's portfolio value fell 16% quarter-over-quarter to $5.2B.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.